Author/Authors :
F. J. Lopez-Escudero ، نويسنده , , L. Arias، نويسنده , , R. Chan، نويسنده , , Geoffrey D. E. Clarke، نويسنده , , T. R. Elworthy، نويسنده , , A. P. D. W. Ford، نويسنده , , A. Guzman، نويسنده , , S. Jaime-Figueroa، نويسنده , , J. R. Jasper، نويسنده , , D. J. Morgans Jr.، نويسنده , , F. Padilla، نويسنده , , A. Perez-Medrano، نويسنده , , C. Quintero، نويسنده , , M. Romero، نويسنده , , L. Sandoval، نويسنده , , S. A. Smith، نويسنده , , T. J. Williams، نويسنده , , D. R. Blue، نويسنده ,
Abstract :
Predominance in the urethra and prostate of the α1A-adrenoceptor subtype, which is believed to be the receptor mediating noradrenaline induced smooth muscle contraction in these tissues, led to the preparation of α1A-selective antagonists to be tested as uroselective compounds for the treatment of benign prostatic hyperplasia. Thus, a number of selective α1A-adrenoceptor antagonists were synthesized and assayed in vitro for potency and selectivity. Dog pharmacokinetic parameters of 12 (RO700004) and its metabolite 40 (RO1104253) were established. The relative selectivity of intravenously administered 12, 40 and standard prazosin to inhibit hypogastric nerve stimulation-induced increases in intraurethral prostatic pressure versus phenylephrine-induced increases in diastolic blood pressure in anesthetized dogs was 76, 71 and 0.6, respectively
